{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cervical-cancer-hpv/background-information/causes/","result":{"pageContext":{"chapter":{"id":"02013d86-5f8b-50e2-8bbc-9e9e5335f72d","slug":"causes","fullItemName":"Causes","depth":2,"htmlHeader":"<!-- begin field 987df77b-ff83-455a-9a2b-c0fec829d8a8 --><h2>What causes cervical cancer?</h2><!-- end field 987df77b-ff83-455a-9a2b-c0fec829d8a8 -->","summary":"","htmlStringContent":"<!-- begin item 3ed2e29a-caf1-4f2d-97d4-7373124c2ec6 --><!-- begin field 28f11aec-6b8b-436c-9412-3ccaa10da815 --><ul><li>Cervical cancer is <a class=\"topic-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/background-information/causes/#role-of-hpv-in-cervical-cancer\">caused</a> by persistent infection with high risk types of human papillomavirus (HPV). <ul><li>HPV16 and HPV18 are responsible for about 75% of cervical cancers.</li><li>Other high risk types are 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82.</li></ul></li><li>Persistent infection is the presence of high risk HPV for longer than two years.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Goodman, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">BMJ, 2016</a>]</p><!-- end field 28f11aec-6b8b-436c-9412-3ccaa10da815 --><!-- end item 3ed2e29a-caf1-4f2d-97d4-7373124c2ec6 -->","topic":{"id":"38328a3b-8997-55f8-afac-19e980523812","topicId":"e2dafa6e-4749-48b2-b981-fa906c90d627","topicName":"Cervical cancer and HPV","slug":"cervical-cancer-hpv","lastRevised":"Last revised in September 2020","chapters":[{"id":"417b3c03-a940-5eb6-8b35-698036862be5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b4186a4a-8c1e-51ad-9743-d00be5b18f3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c2a58da0-8965-5522-8b3d-618890f730d3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2a436c60-1809-5f9f-bf39-409fd07e7af5","slug":"changes","fullItemName":"Changes"},{"id":"6b2a8979-8ca9-5087-a80b-ea14445c034a","slug":"update","fullItemName":"Update"}]},{"id":"c207e9ef-e492-5e67-8986-8b48ff76c55f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4e791e8f-015d-58bd-99ec-2689c4baa3e4","slug":"goals","fullItemName":"Goals"},{"id":"b04fb3a0-7363-5d87-b475-a7ad1e7ca9af","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"af911672-6dba-57d0-b3bf-4058c30f91ff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"16911bc4-aa1d-56b2-aaf3-39695a5692f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9c781faa-cf3f-5dcc-b39d-4c10588cbbfb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"713db7a4-b4c8-55f3-8ca0-e5c0db230466","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e32e97af-cb99-5487-8ceb-1d8db9b2fe5f","slug":"types-of-cervical-cancer","fullItemName":"Types of cervical cancer"},{"id":"02013d86-5f8b-50e2-8bbc-9e9e5335f72d","slug":"causes","fullItemName":"Causes"},{"id":"961e80d0-b721-5756-b1df-56633ce9e5aa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4a62390f-59b9-5d3c-ad78-0394d8900138","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5f216154-2a06-5aee-9270-f2388b590979","slug":"prognosis","fullItemName":"Prognosis"},{"id":"98782e4e-b481-5526-803b-b5f18e566c5d","slug":"complications","fullItemName":"Complications"}]},{"id":"0158af19-7ed5-56ac-a299-796dcf69f9a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a170049-907b-518b-9506-127d186d0a96","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"ae89986b-d468-50ca-b0d4-788dce1cc020","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5aee8849-a5fc-592a-ba2f-161843f6a42e","slug":"cervical-cytology-sample","fullItemName":"Cervical cytology sample"},{"id":"8b13c601-cb6f-536e-a6cc-90001fa3357a","slug":"hpv-screening","fullItemName":"HPV screening"},{"id":"a05197b4-af3e-5fcb-9458-ec6446bb0cb9","slug":"referral","fullItemName":"Referral"}]},{"id":"75bee623-8a4b-5b31-b85b-b1f0cf45212d","fullItemName":"Management","slug":"management","subChapters":[{"id":"3918bf03-5c07-5c8f-bb28-5834e5dc1343","slug":"prevention","fullItemName":"Scenario: Prevention"},{"id":"5d0f88a0-5a31-5e1f-81ee-89cc202d9885","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"64ce0536-0d7d-554e-afc1-7859f158b82c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f4263e46-d3a8-5853-904f-7c0e9b926a1c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b9af798-d073-5ea1-a174-157b46c68062","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e827e587-3f77-5c14-92f8-58f34c105bbe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"22b0924c-0e7d-5a46-b369-dd38ebbc4a39","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f012ac60-98ba-56b3-838a-7924e3544719","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"102ef6c4-0635-5f17-a33b-e2d83ec751b0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f31eeae-6068-5e2c-8097-3666754f067e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","slug":"background-information","fullItemName":"Background information"},"subChapters":[{"id":"a529cac8-54d2-505f-98c3-843a63237273","slug":"role-of-hpv-in-cervical-cancer","fullItemName":"Role of HPV in cervical cancer","depth":3,"htmlHeader":"<!-- begin field 0e938532-1729-4526-a27e-573c23fc99ef --><h3>What is the role of human papillomavirus (HPV) in cervical cancer?</h3><!-- end field 0e938532-1729-4526-a27e-573c23fc99ef -->","summary":null,"htmlStringContent":"<!-- begin item 72d05728-8042-465d-815b-64744241cced --><!-- begin field b33c1778-7c85-48f8-b804-a75596114eb2 --><ul><li>Human papillomavirus (HPV) plays a crucial role in the development of cervical cancer. It has been detected in 99.7% of cervical cancers and is usually transmitted by intimate sexual contact [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">USPSTF, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2014</a>].</li><li>There are more than 130 strains or types of HPV, 40 of which affect the anogenital area [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Public Health Agency of Canada, 2008</a>].<ul><li>At least 15 types are oncogenic and associated with cervical intraepithelial neoplasia (CIN), squamous cell carcinoma, and adenocarcinoma of the cervix — these are known as high risk viruses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">BMJ, 2016</a>].</li></ul></li><li>Infection with oncogenic HPV may result in integration of viral DNA into the host genome, interference with ordered cell growth, immortalization of cells, and cancer.<ul><li>The mechanism is interference of HPV E6 and E7 proteins with the normal cell regulatory functions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">SOGC, 2007</a>].</li></ul></li><li>The development of CIN and cervical cancer is a continuous process: changes in the cervical epithelium become worse and in some women develop into invasive cervical cancer. Changes may regress, but this becomes less likely as the disease progresses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">BMJ, 2016</a>].<ul><li>The annual rate of progression of high-grade squamous CIN to invasive cancer is 1.4% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">BMJ, 2016</a>].</li></ul></li><li>The interval between infection with HPV and progression to invasive carcinoma is usually about 10 years or longer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">WHO, 2014</a>].</li></ul><!-- end field b33c1778-7c85-48f8-b804-a75596114eb2 --><!-- end item 72d05728-8042-465d-815b-64744241cced -->","subChapters":[]},{"id":"c3e8cb55-9eea-5bd6-9693-4a90b8313af9","slug":"persistence-recurrence","fullItemName":"Persistence and recurrence","depth":3,"htmlHeader":"<!-- begin field 59a3d129-cb92-4c73-ad11-3e55be39952d --><h3>Does infection with human papillomavirus persist or recur?</h3><!-- end field 59a3d129-cb92-4c73-ad11-3e55be39952d -->","summary":null,"htmlStringContent":"<!-- begin item 9e20aca6-a072-483b-95af-a604b2c61d90 --><!-- begin field 003c4ad3-6851-48ed-a33c-9921871705fe --><ul><li>Although human papillomavirus (HPV) infection may persist or recur, most genital HPV infections with high-risk oncogenic strains do not develop cancer. <ul><li>The majority (70%–90%) of HPV infections with both high and low risk types are asymptomatic, short-lived, and resolve spontaneously within 1–2 years.</li><li>Persistence of infection with types 16 and 18 is more common than with other high-risk oncogenic strains.</li><li>Infection persists for longer in immunosuppressed women (such as women with HIV).</li></ul></li><li>Genital HPV infection does not cause a vigorous immune response, and only 70–80% of women develop serum antibodies to HPV.<ul><li>It is not known for how long immunity persists after natural infection.</li><li>There appears to be a reduced risk of reinfection with the same HPV type, but re-infection with the same genotype may occur.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">WHO, 2014</a>]</p><!-- end field 003c4ad3-6851-48ed-a33c-9921871705fe --><!-- end item 9e20aca6-a072-483b-95af-a604b2c61d90 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}